FindTrial
Sign In

Liver Transplantation for Unresectable GIST Liver Metastases

Liver Transplantation in Patients With Unresectable GastroIntestinal Stromal Tumors (GIST) Liver Metastases

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04825470
Acronym
TRANSGIST
Enrollment
50
Registered
2021-04-01
Start date
2022-05-31
Completion date
2025-12-31
Last updated
2022-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Stromal Tumor by AJCC V8 Stage, Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Tumor of Duodenum, Gastrointestinal Stromal Tumor of Esophagus (Disorder), Gastrointestinal Stromal Tumor of Large Intestine (Disorder), Gastrointestinal Stromal Tumor of Other Sites, Gastrointestinal Stromal Tumor of Rectum, Gastrointestinal Stromal Tumor of Small Intestine (Disorder), Gastrointestinal Stromal Tumor of Stomach, Gastrointestinal Stromal Tumors, Gastrointestinal Stromal Tumor, Unspecified Site, GIST, GIST, Malignant, Liver Cancer, Liver Carcinoma, Liver Diseases, Liver Mass, Liver Metastases, Liver Neoplasms, Liver Transplantation, Liver Transplant; Complications, Liver Transplant Disorder, Metastases, Metastases to Liver, Metastasis, Metastatic Liver Cancer, Transplant Oncology

Keywords

liver transplantation, gastrointestinal stromal tumor (GIST), Transplant Oncology, liver neoplasms, liver metastases

Brief summary

Liver Transplantation for Unresectable GIST Liver Metastases

Interventions

PROCEDURELiver Transplantation

Liver Transplantation

Sponsors

Hospital Universitario Virgen de la Arrixaca
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* GIST diagnosis (c-Kit, CD34, DOG-1) * Imatinib-sensitive mutation * Non-resectable liver metastases * Abscence of extrahepatic disease * Period greater than two years between primary tumor and metastases diagnosis

Design outcomes

Primary

MeasureTime frameDescription
Overall SurvivalThrough study completion, an average of 2 yearsSurvival
Graft SurvivalThrough study completion, an average of 2 yearsLiver graft Survival

Secondary

MeasureTime frame
Relapse free survivalThrough study completion, an average of 2 years
Disease free survivalThrough study completion, an average of 2 years

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026